Skip to Content

Portrazza FDA Approval History

FDA Approved: Yes (First approved November 24, 2015)
Brand name: Portrazza
Generic name: necitumumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Non-Small Cell Lung Cancer

Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.

Development Timeline for Portrazza

DateArticle
Nov 24, 2015Approval FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.